Reuters logo
BRIEF-Oncology Venture Sweden: Successful prediction of cancer response to LiPlaCis in breast cancer and other tumors by OV's DRP
June 27, 2017 / 10:27 AM / 3 months ago

BRIEF-Oncology Venture Sweden: Successful prediction of cancer response to LiPlaCis in breast cancer and other tumors by OV's DRP

June 27 (Reuters) - ONCOLOGY VENTURE SWEDEN AB:

* SUCCESSFUL PREDICTION OF CANCER RESPONSE TO LIPLACIS® IN BREAST CANCER AND OTHER TUMORS BY OV‘S DRP™ - STRONG SUPPORT FOR RANDOMIZED PHASE 2

* ‍DATA FROM ONGOING LIPLACIS PHASE 1/2 STUDY SHOWS TUMOR RESPONSE TO LIPLACIS CAN BE PREDICTED BY ONCOLOGY VENTURES DRP INDEPENDENT OF TUMOR TYPE AND INCLUDING BREAST CANCER​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below